Product logins

Find logins to all Clarivate products below.


Osteoporosis – Landscape & Forecast – Disease Landscape & Forecast

The osteoporosis therapy market is expected to experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake of Evenity, Prolia / Pralia, and Tymlos / Ostabalo. This growth will be offset to a certain extent by the launch of nonbranded therapies. The relatively low diagnosis and drug treatment rates for osteoporosis, owing to the asymptomatic nature of the disease, will also continue to rein in the market. Other constraints impacting treatment rates include safety concerns associated with bisphosphonates, particularly osteonecrosis of the jaw and atypical femoral fractures, and strict reimbursement policies limiting the use of effective anabolic therapies in low-risk patients. Driven largely by their widespread generic availability and strong physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to the uptake of novel therapies. Emerging therapies will need to demonstrate a favorable clinical risk-benefit balance, at a competitive price, to challenge the bisphosphonates as first-line treatments.

QUESTIONS ANSWERED

  • What are the drivers and constraints in the osteoporosis market, and how will the market evolve over the forecast period?
  • How has Amgen / UCB’s Evenity been integrated into the treatment algorithms in the major markets?
  • What do thought leaders think of the emerging therapies for osteoporosis and current treatments and practices? How will the uptake of emerging agents impact current market-leading therapies?
  • What impact will the generic entries of key brands, such as Prolia / Pralia, have on the osteoporosis market?

CONTENT HIGHLIGHTS

Geography: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading rheumatologists and endocrinologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of osteoporosis by country, with diagnosed and drug-treated population.

Features: 10-year, annualized, drug-level sales and patient share of key osteoporosis therapies through 2033, segmented by brands / generics.

Emerging therapies: Phase 2/3/PR: 1 drug.

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENTS

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast (G7)
Osteoarthritic (OA) pain is prevalent, debilitating, and challenging to manage. Current treatments, including intra-articular agents, NSAIDs, antidepressants, opioids, and antiepileptic drugs, are…